These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 36822363)

  • 61. Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Reinert T; Petersen LMS; Henriksen TV; Larsen MØ; Rasmussen MH; Johansen AFB; Øgaard N; Knudsen M; Nordentoft I; Vang S; Krag SRP; Knudsen AR; Mortensen FV; Andersen CL
    Int J Cancer; 2022 May; 150(9):1537-1548. PubMed ID: 34994972
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC).
    Chen K; Zhao H; Shi Y; Yang F; Wang LT; Kang G; Nie Y; Wang J
    Clin Cancer Res; 2019 Dec; 25(23):7058-7067. PubMed ID: 31439586
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
    Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
    Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
    [TBL] [Abstract][Full Text] [Related]  

  • 64. ctDNA as promising tool for the assessment of minimal residual disease (MRD) and the need of an adjuvant treatment in gastroesophageal adenocarcinoma.
    Piva VM; De Grandis MC; Zuin IS; Angerilli V; Nappo F; Alfieri R; Ahcene Djaballah S; Murgioni S; Bergamo F; Fassan M; Valmasoni M; Lonardi S
    Updates Surg; 2023 Feb; 75(2):305-312. PubMed ID: 36272058
    [TBL] [Abstract][Full Text] [Related]  

  • 65. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prospects and challenges of circulating tumor DNA in precision medicine of hepatocellular carcinoma.
    Weng J; Atyah M; Zhou C; Ren N
    Clin Exp Med; 2020 Aug; 20(3):329-337. PubMed ID: 32239299
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma.
    Ueberroth BE; Jones JC; Bekaii-Saab TS
    Pancreatology; 2022 Sep; 22(6):741-748. PubMed ID: 35725696
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
    Lipsyc-Sharf M; de Bruin EC; Santos K; McEwen R; Stetson D; Patel A; Kirkner GJ; Hughes ME; Tolaney SM; Partridge AH; Krop IE; Knape C; Feger U; Marsico G; Howarth K; Winer EP; Lin NU; Parsons HA
    J Clin Oncol; 2022 Aug; 40(22):2408-2419. PubMed ID: 35658506
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma.
    Azzi G; Tavallai M; Aushev VN; Koyen Malashevich A; Botta GP; Tejani MA; Hanna D; Krinshpun S; Malhotra M; Jurdi A; Aleshin A; Kasi PM
    Oncologist; 2023 Mar; 28(3):220-229. PubMed ID: 36562592
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evolving Role of Circulating Tumor DNA and Emerging Targeted Therapy in Colorectal Cancer.
    Malla M; Parikh AR
    Hematol Oncol Clin North Am; 2022 Jun; 36(3):583-601. PubMed ID: 35577710
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Liquid biopsies for residual disease and recurrence.
    Wan JCM; Mughal TI; Razavi P; Dawson SJ; Moss EL; Govindan R; Tan IB; Yap YS; Robinson WA; Morris CD; Besse B; Bardelli A; Tie J; Kopetz S; Rosenfeld N
    Med; 2021 Dec; 2(12):1292-1313. PubMed ID: 35590147
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review.
    Abdallah R; Taly V; Zhao S; Pietrasz D; Bachet JB; Basile D; Mas L; Zaanan A; Laurent-Puig P; Taieb J
    Cancer Treat Rev; 2020 Jul; 87():102028. PubMed ID: 32485509
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis.
    Benesova L; Ptackova R; Halkova T; Semyakina A; Svaton M; Fiala O; Pesek M; Minarik M
    Pathol Oncol Res; 2022; 28():1610308. PubMed ID: 35837614
    [No Abstract]   [Full Text] [Related]  

  • 74. Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer.
    Adams AM; Vreeland TJ; Newhook TE
    J Gastrointest Cancer; 2023 Dec; 54(4):1071-1081. PubMed ID: 36562938
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
    Peng Y; Mei W; Ma K; Zeng C
    Front Oncol; 2021; 11():763790. PubMed ID: 34868984
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical application and prospect of MRD evaluation in lung cancer based on ctDNA level: A review.
    Yan X; Liu C
    Tumori; 2023 Aug; 109(4):356-362. PubMed ID: 35815471
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer.
    Chen K; Kang G; Zhang Z; Lizaso A; Beck S; Lyskjær I; Chervova O; Li B; Shen H; Wang C; Li B; Zhao H; Li X; Yang F; Kanu N; Wang J
    BMC Med; 2023 Jul; 21(1):255. PubMed ID: 37452374
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring.
    Choi WJ; Ivanics T; Gravely A; Gallinger S; Sapisochin G; O'Kane GM
    Ann Surg Oncol; 2023 Jun; 30(6):3849-3863. PubMed ID: 36808320
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.
    Sun Y; Zhu C; Xu F; Cui S; Guan X
    Clin Breast Cancer; 2023 Jun; 23(4):339-349. PubMed ID: 36966079
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Clinical Circulating Tumor DNA Testing for Precision Oncology.
    Kim H; Park KU
    Cancer Res Treat; 2023 Apr; 55(2):351-366. PubMed ID: 36915242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.